NEW YORK, Oct. 19 - Invitrogen has been granted a non-exclusive sub-license from Gryphon Sciences to use its Native Chemical Ligation patent, which allow researchers to synthesize proteins using chemical, rather than biological means, Gryphon said on Friday.

The patent, numbered 6,184,344 and entitled "Synthesis of Proteins by Native Chemical Ligation," covers processes for making proteins that retain the biologic activity of the native molecule and can have specific functionality built into them, according to Gryphon. 

Financials terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.